We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
Read MoreHide Full Article
Key Takeaways
HOLX posted $464.4M Diagnostics revenues in Q1' 26, down 1.3% as COVID-19 and legacy STI test sales fell.
Hologic saw stronger BV, CV/TV test sales and expanded Panther Fusion assays to grow its diagnostics menu.
Hologic gained FDA approval for Aptima HPV primary screening and expanded EU clearance for the Genius system.
Hologic (HOLX - Free Report) posted Diagnostics revenues of $464.4 million in the first quarter of fiscal 2026, down 1.3% from last year. The segment remains anchored by the molecular diagnostic assays, which run on the base Panther and the combined Panther Fusion advanced instrumentation systems. However, the quarter showed some pressure, with Molecular Diagnostics revenues declining 3.5%, mainly due to weaker sales of COVID-19 tests and legacy sexually transmitted infections (STI) assays.
The decrease was partially offset by stronger sales of BV, CV/TV tests and Panther Fusion assays. Hologic is actively targeting the vast U.S. vaginitis market by driving awareness and reimbursement for the high-throughput offering. Panther Fusion’s open access functionality allows customers to consolidate lab-developed tests (LDTs) and in vitro diagnostic (IVD) assays on a single platform. Last year, Hologic secured FDA 510(k) clearance and CE-IVDR marking for the Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays, supporting its menu diversification strategy. Biotheranostics is also seeing higher adoption of its Breast Cancer Index test, which helps guide extended endocrine therapy.
On the other side, Cytology and perinatal revenues rose 1.1% in the quarter. Sales of ThinPrep Pap tests were impacted by the U.S.-China tensions and other Chinese policies, dragging down Asia-Pacific revenues. The Genius Digital Diagnostics System, which blends novel artificial intelligence (AI) algorithms with advanced digital imaging to detect pre-cancerous lesions and cervical cancer cells, could emerge as a meaningful growth driver.
Recent developments also support prospects. In February 2026, the Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening, expanding the Cervical Health Portfolio. The Genius System also gained expanded CE marking in the European Union, now approved to image and review both cell and tissue specimens.
Updates From Hologic’s Peers: BDX & ABT
Becton, Dickinson and Company (BDX - Free Report) , or BD, has obtained CE Mark for the Revello Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries. The development comes at a time when lower???extremity peripheral artery disease (PAD), in which iliac artery disease is a key component, continues to place a substantial disability burden across the EU's aging population.
Abbott’s (ABT - Free Report) CardioMEMS HERO, a next-generation pulmonary artery (PA) pressure reader, has received the FDA’s approval. The reader contains new design features to help empower heart failure patients and their clinicians with the daily insights they need to detect and combat heart failure progression. Abbott also secured CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled, its latest advancement in the pulsed field ablation (PFA) technology portfolio to treat atrial fibrillation in patients.
HOLX Stock Performance, Valuation and Estimates
In the past year, Hologic shares have risen 17.4% against the industry’s 4.2% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward, five-year price-to-sales (P/S) of 3.88X, lower than its median and the industry average.
Image Source: Zacks Investment Research
Here’s a quick look at Hologic’s earnings estimate trend.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
Key Takeaways
Hologic (HOLX - Free Report) posted Diagnostics revenues of $464.4 million in the first quarter of fiscal 2026, down 1.3% from last year. The segment remains anchored by the molecular diagnostic assays, which run on the base Panther and the combined Panther Fusion advanced instrumentation systems. However, the quarter showed some pressure, with Molecular Diagnostics revenues declining 3.5%, mainly due to weaker sales of COVID-19 tests and legacy sexually transmitted infections (STI) assays.
The decrease was partially offset by stronger sales of BV, CV/TV tests and Panther Fusion assays. Hologic is actively targeting the vast U.S. vaginitis market by driving awareness and reimbursement for the high-throughput offering. Panther Fusion’s open access functionality allows customers to consolidate lab-developed tests (LDTs) and in vitro diagnostic (IVD) assays on a single platform. Last year, Hologic secured FDA 510(k) clearance and CE-IVDR marking for the Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays, supporting its menu diversification strategy. Biotheranostics is also seeing higher adoption of its Breast Cancer Index test, which helps guide extended endocrine therapy.
On the other side, Cytology and perinatal revenues rose 1.1% in the quarter. Sales of ThinPrep Pap tests were impacted by the U.S.-China tensions and other Chinese policies, dragging down Asia-Pacific revenues. The Genius Digital Diagnostics System, which blends novel artificial intelligence (AI) algorithms with advanced digital imaging to detect pre-cancerous lesions and cervical cancer cells, could emerge as a meaningful growth driver.
Recent developments also support prospects. In February 2026, the Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening, expanding the Cervical Health Portfolio. The Genius System also gained expanded CE marking in the European Union, now approved to image and review both cell and tissue specimens.
Updates From Hologic’s Peers: BDX & ABT
Becton, Dickinson and Company (BDX - Free Report) , or BD, has obtained CE Mark for the Revello Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries. The development comes at a time when lower???extremity peripheral artery disease (PAD), in which iliac artery disease is a key component, continues to place a substantial disability burden across the EU's aging population.
Abbott’s (ABT - Free Report) CardioMEMS HERO, a next-generation pulmonary artery (PA) pressure reader, has received the FDA’s approval. The reader contains new design features to help empower heart failure patients and their clinicians with the daily insights they need to detect and combat heart failure progression. Abbott also secured CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled, its latest advancement in the pulsed field ablation (PFA) technology portfolio to treat atrial fibrillation in patients.
HOLX Stock Performance, Valuation and Estimates
In the past year, Hologic shares have risen 17.4% against the industry’s 4.2% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward, five-year price-to-sales (P/S) of 3.88X, lower than its median and the industry average.
Image Source: Zacks Investment Research
Here’s a quick look at Hologic’s earnings estimate trend.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.